ulfamid 20 mg filmsko obložene tablete
krka, d.d., novo mesto - famotidin - filmsko obložena tableta - famotidin 20 mg / 1 tableta - famotidin
ulfamid 20 mg filmsko obložene tablete
krka, d.d., novo mesto - famotidin - filmsko obložena tableta - famotidin 20 mg / 1 tableta - famotidin
ulfamid 40 mg filmsko obložene tablete
krka, d.d., novo mesto - famotidin - filmsko obložena tableta - famotidin 40 mg / 1 tableta - famotidin
ulfamid 40 mg filmsko obložene tablete
krka, d.d., novo mesto - famotidin - filmsko obložena tableta - famotidin 40 mg / 1 tableta - famotidin
ulfamid 20 mg filmsko obložene tablete
krka, d.d., novo mesto - famotidin - filmsko obložena tableta - famotidin 20 mg / 1 tableta - famotidin
quamatel 20 mg prašek in vehikel za raztopino za injiciranje
famotidin - prašek in vehikel za raztopino za injiciranje - famotidin 20 mg / 1 viala - famotidin
atazanavir accord 300 mg trde kapsule
atazanavir - kapsula, trda - atazanavir 300 mg / 1 kapsula - atazanavir
stelfonta
qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - psi - za zdravljenje ne-resectable, non-metastatskim (ki uprizoritev) podkožnega jambor celice tumorji, ki se nahajajo na ali v distalni komolca ali hock, in non-resectable, ne metastatskim kožne jambor celice tumorjev pri psih.
vosevi
gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitis c, kronični - antivirusi za sistemsko uporabo - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (glej točki 4. 2, 4. 4 in 5.
calquence
astrazeneca ab - acalabrutinib - levkemija, limfocitna, kronična, b-celica - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.